BioMed Realty Trust Announces Public Offering Of 15,000,000 Shares Of Common Stock

 BioMed Realty Trust Announces Public Offering Of 15,000,000 Shares Of Common

PR Newswire

SAN DIEGO, March 26, 2013

SAN DIEGO, March 26, 2013 /PRNewswire/ -- BioMed Realty Trust, Inc. (NYSE:
BMR) today announced it has commenced a public offering of 15,000,000 shares
of its common stock pursuant to an effective shelf registration statement
filed with the Securities and Exchange Commission. BioMed Realty expects to
use the net proceeds of the offering to fund a portion of the purchase price
for the recently announced, pending acquisition of Wexford Science &
Technology, LLC, to repay a portion of the outstanding indebtedness under its
unsecured line of credit and for other general corporate and working capital
purposes. The acquisition of Wexford Science & Technology is subject to the
receipt of lender, ground lessor and other third-party consents, waivers of
rights of first offer and customary closing conditions, and there can be no
assurances that the acquisition will close on the terms described, or at all.
All of the shares will be offered by the company.

BioMed Realty also expects to grant the underwriters a 30-day option to
purchase up to an additional 2,250,000 shares of its common stock. Morgan
Stanley & Co. LLC, Raymond James & Associates, Inc., UBS Securities LLC, Wells
Fargo Securities, LLC and KeyBanc Capital Markets Inc. are the joint
book-running managers for the offering.

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy any of the offered shares, nor shall there be any sale of
such shares in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of such state or other jurisdiction. The offering
of BioMed Realty's common stock will be made only by means of a prospectus and
a related prospectus supplement, copies of which, when available, may be
obtained by contacting Morgan Stanley & Co. LLC, Attn: Prospectus Department,
180 Varick Street, 2nd Floor, New York, NY 10014, at 1-866-718-1649 or by
email at; Raymond James & Associates, Inc., 880
Carillon Parkway, St. Petersburg, FL 33716, by calling toll-free at
1-800-248-8863 or by email at; UBS Securities LLC,
Attention: Prospectus Department, 299 Park Avenue, New York, New York 10171,
or toll-free at 1-888-827-7275; Wells Fargo Securities, LLC, Attention: Equity
Syndicate Department, 375 Park Avenue, New York, New York 10152, at
1-800-326-5897 or by email at; or KeyBanc
Capital Markets Inc., Attention: Prospectus Delivery Department, 127 Public
Square, 4th Floor, Cleveland, Ohio 44114, telephone: 1-800-859-1783.

About BioMed Realty Trust

BioMed Realty delivers optimal real estate solutions for biotechnology and
pharmaceutical companies, scientific research institutions, government
agencies and other entities involved in the life science industry. BioMed
Realty owns or has interests in properties comprising approximately 13.2
million rentable square feet. The company's properties are located
predominantly in the major U.S. life science markets of Boston, San Francisco,
Maryland, San Diego, New York/New Jersey, Pennsylvania and Seattle, which have
well-established reputations as centers for scientific research.

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 based on current
expectations, forecasts and assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially. These risks
and uncertainties include, without limitation: the possibility that the
company's merger with Wexford Science & Technology may not occur on the terms
described, or at all; failure to manage effectively the company's growth and
expansion into new markets, or to complete or integrate acquisitions and
developments successfully, including the company's merger with Wexford Science
& Technology and related development projects; the company's ability to meet
projected yields on properties, including projected yields on properties to be
acquired in connection with the company's merger with Wexford Science &
Technology; general risks affecting the real estate industry (including,
without limitation, the inability to enter into or renew leases, dependence on
tenants' financial condition, and competition from other developers, owners
and operators of real estate); adverse economic or real estate developments in
the life science industry or the company's target markets; risks associated
with the availability and terms of financing, the use of debt to fund
acquisitions, developments and other investments, and the ability to refinance
indebtedness as it comes due; failure to maintain the company's investment
grade credit ratings with the ratings agencies; reductions in asset valuations
and related impairment charges; risks and uncertainties affecting property
development and construction; risks associated with downturns in foreign,
domestic and local economies, changes in interest rates and foreign currency
exchange rates, and volatility in the securities markets; ownership of
properties outside of the United States that subject the company to different
and potentially greater risks than those associated with the company's
domestic operations; risks associated with the company's investments in loans,
including borrower defaults and potential principal losses; potential
liability for uninsured losses and environmental contamination; risks
associated with the company's potential failure to qualify as a REIT under the
Internal Revenue Code of 1986, as amended, and possible adverse changes in tax
and environmental laws; and risks associated with the company's dependence on
key personnel whose continued service is not guaranteed. For a further list
and description of such risks and uncertainties, see the reports filed by the
company with the Securities and Exchange Commission, including the company's
most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The
company disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.

SOURCE BioMed Realty Trust, Inc.

Contact: Rick Howe, Senior Director, Corporate Communications, 858.207.5859,
Press spacebar to pause and continue. Press esc to stop.